Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1993

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

A randomized comparative open study of the effects of two oral

contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism.

AUTHORS

Kakis G; Powell M; Marshall A; Steiner G

SOURCE

CONTRACEPTION. 1993 Feb;47(2):131-48.

ABSTRACT

This study assessed serum lipid, lipoprotein, and apolipoprotein changes during 1 year in 3 groups of nonsmoking

women: 1) Triphasic(R); 2) Ortho(R) 7/7/7; 3) Controls. Both oral contraceptives (OCs) contain the estrogen, ethinyl

estradiol (EE), in combination with a progestin in 3 different ratios during each cycle. The progestin in Triphasil is

d-norgestrel, as the dl-racemate norgestrel (NG), whereas that in Ortho 7/7/7 is norethindrone (NE). Total plasma

triglycerides were elevated significantly from baseline (p<0.001) with Ortho 7/7/7 at 3, 6, and 12 months, but only at 3

months with Triphasil (p=0.047). Triglycerides were elevated in the LDL fraction with Ortho 7/7/7 at 3 months

(p=0.001), 6 months (p=0.018), and 12 months (p=0.010). In contrast, LDL triglycerides were not significantly

elevated with Triphasil. Similarly, IDL triglycerides were elevated only in the Ortho 7/7/7 group at 6 months (p=0.002)

and 12 months (p=0.001). Plasma cholesterol was elevated only in the Ortho 7/7/7 group at 3, 6, and 12 months with

p values of 0.009, 0.005, and 0.010, respectively. Cholesterol in the LDL fraction was elevated with Ortho 7/7/7 at 12

months (p=0.002). Plasma apolipoprotein B (apo B) increased at least 24% from baseline for both the Triphasil and

Ortho 7/7/7 groups at 3 and 12 months (p<0.001). However, at 6 months, apo B increased only 17.7% (P=0.008) with

triphasil compared to 29.7% (p<0.001) with Ortho 7/7/7 at 6 months. Apo B was increased (p<0.001) in LDL with

Triphasil at 3 months only, whereas LDL apo B was increased at 3, 6, and 12 months with Ortho 7/7/7 (p<0.01,

p=0.20, and p=0.012, respectively). Apo B increased dramatically in the IDL fraction of both OC user populations,

with the range of increases being between 48% and 87% during the year (p<0.001 at all times). Significant

elevations in VLDL apo B ranged from 71% to 106% (p<0.001) with Triphasil and from 42.4% (p<0.005) to 72.6%

(p<0.001) with Ortho 7/7/7. In conclusion, NE and dl-norgestrel formulations have divergent effects on several

components of plasma lipoprotein and lipid metabolism, but both products increase plasma and IDL apo B.

(PubHealth.info Document ID: CONT2T 4525-06)

PubHealth.info NOTE: The author(s) of this article titled, "A randomized comparative open study of the effects of two

oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism.", is(are) Kakis G; Powell M; Marshall A; Steiner

G. The source of this article is "CONTRACEPTION. 1993 Feb;47(2):131-48.". This article was published in 1993 in

English language(s). (PubHealth.info® Document ID: CONT2T 4525-06. All rights reserved with PubHealth.info) PIN:

9525

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.